Open Beta
MetriLume

US marketsNBIX

SEC-sourced researchBeta

NBIX

NEUROCRINE BIOSCIENCES INC

Company comparison ↗

Data passport

CIK
0000914475
Exchange
Nasdaq
Business activity
— · SIC 2836
Financial inputs
6/6
Filing date
Sep 28, 2026
SEC registry record
Operating company

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2023: 1,887,100,000.0000 USD; December 2024: 2,355,300,000.0000 USD; December 2025: 2,860,500,000.0000 USD2.9B USD0 USD0December 2023December 2024December 2025
NBIX · Exact amounts and source periods · USD
Period endRevenueFiling date
December 20231,887,100,000.0000Feb 11, 2026
December 20242,355,300,000.0000Feb 11, 2026
December 20252,860,500,000.0000Feb 11, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 20252,860,500,000.0000478,600,000.0000782,700,000.00004,631,500,000.00001,378,400,000.0000Feb 11, 2026
December 20242,355,300,000.0000341,300,000.0000595,400,000.00003,718,700,000.00001,129,000,000.0000Feb 11, 2026
December 20231,887,100,000.0000249,700,000.0000389,900,000.0000——Feb 11, 2026

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenueFromContractWithCustomerExcludingAssessedTax$2.86BDecember 2025Feb 11, 202610-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax$2.36BDecember 2024Feb 11, 202610-K
Net incomeNetIncomeLoss$478.6MDecember 2025Feb 11, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities$782.7MDecember 2025Feb 11, 202610-K
Total assetsAssets$4.63BDecember 2025Feb 11, 202610-K
Total liabilitiesLiabilities$1.38BDecember 2025Feb 11, 202610-K

New filings

Explore methodology ↗